Status:
COMPLETED
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
This study compared the blunting effect of aliskiren and valsartan monotherapies on exercise-induced rises in systolic blood pressure in patients with mild to moderate essential hypertension.
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Mean sitting systolic blood pressure ≥ 140 mmHg and \< 180 mmHg measured at rest
- Patients able to exercise and to reach 85% of their predicted heart rate during a standard exercise test on a treadmill according to the Bruce Protocol
- Exclusion criteria:
- Patients not confident in exercising or not able to exercise
- Absolute contraindication to exercise
- Mean sitting systolic blood pressure ≥ 180 mmHg and/or mean sitting diastolic blood pressure ≥ 110 mmHg measured at rest
- Other protocol-defined inclusion/exclusion criteria applied to the study.
Exclusion
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT00819767
Start Date
February 1 2009
End Date
October 1 2009
Last Update
June 28 2011
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Site
Pardubice, Czechia
2
Investigative Site
Prague, Czechia
3
Investigative Site
Budapest, Hungary
4
Investigative Site
Nyíregyháza, Hungary